SEC Form 4 · accession 0001209191-17-051333
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew J D'Onofrio
Officer — Exec VP, Chief Bus. Officer
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 4:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2017 | J | 1,115 | $2.15 | A | 225,723 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c).